

## **Curriculum Vitae Dr Elaine Sullivan**

Academic degree: PhD in Molecular Biology and Virology, University of Edinburgh

Occupation: Chief Executive Officer of Carrick Therapeutics Ltd.

Place of residence: Dublin, Republic of Ireland

### **Personal data**

Year of birth: 1961

Nationality: British

### **Member of the Supervisory Board of Evotec SE**

First appointed on 09 June 2015

Last elected at the Annual General Meeting 09 June 2015 until the Annual General Meeting, which will decide on the approval of the members of the Supervisory Board for fiscal year 2018

### **Education**

1983 – 1987 University of Edinburgh  
Conferral of a doctorate (PhD)

1979 – 1983 University of Glasgow  
Bachelor

### **Professional career**

Since 2015 Carrick Therapeutics Ltd.  
Chief Executive Officer

2011 – 2014 Eli Lilly & Company  
Vice President Global External Research and Development

1995 – 2010 AstraZeneca AB  
Various positions, most recently Vice-President R&D, New Opportunities

## **Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises**

IP Group plc (Member of the Supervisory Board)

## **Other significant activities besides the Supervisory Board mandate**

n/a

## **Relevant knowledge, skills and experience**

Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 for a term of four years. Her current term will expire at the end of the AGM held in the year 2019. Since January 2015, Dr Sullivan has been Chief Executive Officer of Carrick Therapeutics Ltd, a new European oncology company. Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca. She has over 25 years of international experience working in the Pharmaceutical industry in the US, Switzerland and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly's Capital Fund partners. Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice-President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca's virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships. Since July 2015, Dr Elaine Sullivan has been serving as Member of the Supervisory Board of the IP Group plc.

Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor's degree in Molecular Biology from the University of Glasgow, UK.

Due to her extensive knowledge of various aspects of drug discovery and development and her focus on developing external partnerships including spin-outs, joint ventures, and strategic alliances Dr Sullivan ideally complements the future Supervisory Board of Evotec SE.

## **Personal or business relationships in accordance with section 5.4.1 paragraphs 6 to 8 of the German Corporate Governance Code**

In the opinion of the Supervisory Board, Dr Elaine Sullivan and Evotec SE, its affiliates, the bodies of Evotec SE or a significant shareholder in Evotec SE, have no personal or business relationships that an objective judging shareholder would consider authoritative for their voting decision. Shareholders who directly or indirectly hold more than 10% of the Company's voting shares are considered as significant shareholders.